A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tetrabenazine (Xenazine)

indicated for the treatment of chorea associated with Huntington's disease.

First FDA approval2008-11-24
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$66.1M in CY2024 Part D spend44K claims · 8K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.785/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.993
Across all dosage forms in distribution.
Highest NADAC
$1.20
Range is tight.
Plans with PA
580 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Tetrabenazine used for?

indicated for the treatment of chorea associated with Huntington's disease.

Is there a generic for Tetrabenazine?

Yes. 15 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Tetrabenazine?

Across 329 Part D plans, Tetrabenazine averages $0.993/unit (NADAC). Lowest available: $0.785/unit. Highest in distribution: $1.20/unit.

Is Tetrabenazine on the FDA shortage list?

No. Tetrabenazine is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.